Genentech To Start Pivotal Trial Of Bispecific Antibody In Hemophilia A
Executive Summary
In a small Japanese study of 18 patients with hemophilia A, anti-Factor IXa/Factor X antibody ACE910 looks very effective for reducing bleeding, including in patients who have failed on earlier treatment.